[go: up one dir, main page]

MX2009005921A - Formulacion en polvo del valganciclovir. - Google Patents

Formulacion en polvo del valganciclovir.

Info

Publication number
MX2009005921A
MX2009005921A MX2009005921A MX2009005921A MX2009005921A MX 2009005921 A MX2009005921 A MX 2009005921A MX 2009005921 A MX2009005921 A MX 2009005921A MX 2009005921 A MX2009005921 A MX 2009005921A MX 2009005921 A MX2009005921 A MX 2009005921A
Authority
MX
Mexico
Prior art keywords
valganciclovir
powder formulation
dosage forms
pharmaceutical dosage
cytomegalovirus
Prior art date
Application number
MX2009005921A
Other languages
English (en)
Inventor
Martin Howard Infeld
Navnit Hargovindas Shah
Maria Oksana Bachynsky
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39410167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009005921(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009005921A publication Critical patent/MX2009005921A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención proporciona nuevas formas farmacéuticas sólidas de dosificación de valganciclovir clorhidrato para la administración oral, después de haberse constituido en agua. Estas nuevas formas farmacéuticas de dosificación son útiles para el tratamiento o control de virus, tales como el virus herpes simple y el citomegalovirus.
MX2009005921A 2006-12-13 2007-12-03 Formulacion en polvo del valganciclovir. MX2009005921A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87463406P 2006-12-13 2006-12-13
PCT/EP2007/063151 WO2008071573A2 (en) 2006-12-13 2007-12-03 Powder formulation for valganciclovir

Publications (1)

Publication Number Publication Date
MX2009005921A true MX2009005921A (es) 2009-06-17

Family

ID=39410167

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005921A MX2009005921A (es) 2006-12-13 2007-12-03 Formulacion en polvo del valganciclovir.

Country Status (31)

Country Link
US (6) US20080146591A1 (es)
EP (1) EP2101733B1 (es)
JP (1) JP5111517B2 (es)
KR (1) KR101116553B1 (es)
CN (1) CN101541310B (es)
AR (1) AR065541A1 (es)
AU (1) AU2007332640B2 (es)
BR (1) BRPI0720118B8 (es)
CA (1) CA2671470C (es)
CL (1) CL2007003564A1 (es)
CO (1) CO6220902A2 (es)
CR (1) CR10822A (es)
DK (1) DK2101733T3 (es)
ES (1) ES2391912T3 (es)
HR (1) HRP20121033T1 (es)
IL (1) IL198854A (es)
MA (1) MA31280B1 (es)
MX (1) MX2009005921A (es)
MY (1) MY152540A (es)
NO (1) NO339838B1 (es)
NZ (1) NZ577179A (es)
PE (1) PE20081578A1 (es)
PL (1) PL2101733T3 (es)
PT (1) PT2101733E (es)
RS (1) RS52457B (es)
RU (1) RU2440118C2 (es)
SI (1) SI2101733T1 (es)
TW (1) TWI341730B (es)
UA (1) UA93599C2 (es)
WO (1) WO2008071573A2 (es)
ZA (1) ZA200903840B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2257294A2 (en) * 2008-03-07 2010-12-08 Ray W. Exley Treatment of herpes virus related diseases
CN102048677B (zh) * 2009-11-09 2014-03-05 杭州赛利药物研究所有限公司 一种盐酸缬更昔洛韦固体制剂及其制备方法
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
US8969361B2 (en) * 2012-04-20 2015-03-03 Annji Pharmaceutical Co., Ltd. Cyclopropanecarboxylate esters of purine analogues
WO2014106962A1 (ko) 2013-01-07 2014-07-10 삼아제약 주식회사 향상된 용해도를 갖는 신규한 속용성 과립제형
EP3027215B1 (en) * 2013-08-02 2017-05-03 Ali Raif Ilaç Sanayi ve Ticaret Anonim Sirketi Powder formulation of valganciclovir
CN104055746B (zh) * 2014-07-12 2017-06-30 河北仁合益康药业有限公司 一种盐酸缬更昔洛韦包衣片剂组合物
RU2720805C1 (ru) * 2019-05-22 2020-05-13 Общество с ограниченной ответственностью "Трейдсервис" Фармацевтическая композиция валганцикловира
US20220226322A1 (en) 2019-05-31 2022-07-21 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors
CN110613718A (zh) * 2019-09-19 2019-12-27 湖北科益药业股份有限公司 一种缬更昔洛韦组合物
CN110934823B (zh) * 2019-12-27 2022-03-01 湖北康源药业有限公司 一种盐酸缬更昔洛韦口服溶液及制备方法
WO2021161317A1 (en) * 2020-02-12 2021-08-19 Cts Chemical Industries Ltd. Stable pharmaceutical compositions comprising valgancyclovir and uses thereof
CN114028347B (zh) * 2021-11-30 2023-05-12 海南皇隆制药股份有限公司 注射用帕瑞昔布钠及其制备方法
CN115569113B (zh) * 2022-09-19 2023-11-10 江苏汉晨药业有限公司 一种盐酸缬更昔洛韦口服溶液

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU191542B (en) 1983-04-08 1987-03-30 Boehringer Ingelheim Ltd Process for production of pastiles containing dipyridamel independent from ph with regulated output of the active substance
US5856481A (en) 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5840890A (en) 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
CA2305535A1 (en) * 1997-10-03 1999-04-15 Gopadi M. Venkatesh Controlled release solid dosage forms of lithium carbonate
US6221917B1 (en) * 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CA2244097A1 (en) * 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
US20020143058A1 (en) * 2001-01-24 2002-10-03 Taro Pharmaceutical Inductries Ltd. Process for preparing non-hygroscopic sodium valproate composition
DK1459739T3 (da) 2003-03-19 2008-05-19 Jordanian Pharmaceutical Mfg Ikke-hydroskopiske farmaceutiske sammensætninger indeholdende ikke-hydratiserede quinolin-carboxylsyrer
WO2005021549A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Amorphous valganciclovir hydrochloride
ATE403418T1 (de) * 2004-03-10 2008-08-15 Ranbaxy Lab Ltd Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid
KR20080037732A (ko) 2005-08-22 2008-04-30 노파르티스 아게 ｐＨ-의존성 약물, ｐＨ 개질제 및 지연제를 포함하는제약학적 조성물

Also Published As

Publication number Publication date
WO2008071573A3 (en) 2008-11-27
CN101541310B (zh) 2012-11-07
US20130150382A1 (en) 2013-06-13
CR10822A (es) 2009-06-25
IL198854A0 (en) 2010-02-17
MA31280B1 (fr) 2010-04-01
KR20090086469A (ko) 2009-08-12
SI2101733T1 (sl) 2012-12-31
EP2101733A2 (en) 2009-09-23
RU2009126616A (ru) 2011-01-20
KR101116553B1 (ko) 2012-03-13
PL2101733T3 (pl) 2013-02-28
MY152540A (en) 2014-10-15
NO20092254L (no) 2009-07-09
AU2007332640B2 (en) 2011-04-07
US20190117775A1 (en) 2019-04-25
DK2101733T3 (da) 2013-02-04
US20150057296A1 (en) 2015-02-26
UA93599C2 (en) 2011-02-25
AU2007332640A1 (en) 2008-06-19
US20080146591A1 (en) 2008-06-19
US20180153998A1 (en) 2018-06-07
CN101541310A (zh) 2009-09-23
RU2440118C2 (ru) 2012-01-20
CL2007003564A1 (es) 2008-07-18
HRP20121033T1 (hr) 2013-01-31
PT2101733E (pt) 2012-10-30
JP2010513237A (ja) 2010-04-30
ES2391912T3 (es) 2012-12-03
US20170266286A1 (en) 2017-09-21
AR065541A1 (es) 2009-06-17
BRPI0720118B1 (pt) 2020-11-17
EP2101733B1 (en) 2012-09-26
PE20081578A1 (es) 2008-11-12
US11185588B2 (en) 2021-11-30
BRPI0720118B8 (pt) 2021-05-25
JP5111517B2 (ja) 2013-01-09
TWI341730B (en) 2011-05-11
US9642911B2 (en) 2017-05-09
TW200840585A (en) 2008-10-16
US8889109B2 (en) 2014-11-18
NO339838B1 (no) 2017-02-06
CA2671470C (en) 2012-05-01
CA2671470A1 (en) 2008-06-19
BRPI0720118A2 (pt) 2014-01-14
NZ577179A (en) 2011-12-22
ZA200903840B (en) 2010-03-31
WO2008071573A2 (en) 2008-06-19
IL198854A (en) 2014-06-30
CO6220902A2 (es) 2010-11-19
RS52457B (en) 2013-02-28

Similar Documents

Publication Publication Date Title
MY152540A (en) Powder formulation for valganciclovir
IL199152A (en) Annals 2 - (piperidine-4-ram) -4-phenoxy or phenylamino-pyrimidine, containing and containing pharmaceutical preparations for the preparation of viral infections
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MY141025A (en) Dose forms
MY179392A (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
IL206296A (en) History of aminopyrazole, and their medicinal products and their use in the preparation of drugs for the prevention and treatment of diseases
IL200116A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
IL195142A (en) Processed arylaimidazolone and triazolone, their preparation process, pharmaceutical preparations containing them for the treatment or prevention of diseases
IN2012DN02730A (es)
IN2012DN00754A (es)
MX2008012422A (es) Derivados de furano y tiofeno, pirrol substituido con pirimidinil y piridil como inhibidores de cinasa.
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
WO2008127364A3 (en) Antiviral compounds and use thereof
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2009014235A (es) 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
NO20081844L (no) Terapeutiske forbindelser
MXPA05008866A (es) Pirimidinas sustituidas con indano inhibidoras de la replicacion del virus de inmunodeficiencia humana.
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
MX2012006430A (es) Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide.
AP2150A (en) Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication.
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
WO2012030914A8 (en) 4-azolylaminoquinazoline derivatives and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration